• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    iShares Biotechnology ETF (NQ:IBB)

    176.12 +3.93 (+2.28%)
    Streaming Delayed Price Updated: 11:36 AM EDT, Apr 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about iShares Biotechnology ETF

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    28 29 Next >
    News headline image
    Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
    In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF... 
    Via MarketMinute
    Topics ETFs Intellectual Property Stocks
    News headline image
    DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
    iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
    Via The Motley Fool
    Topics Derivatives ETFs Regulatory Compliance
    News headline image
    QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
    H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure. 
    Via Stocktwits
    Topics Initial Public Offering
    PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
    Via Stocktwits
    Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗
    Via Stocktwits
    News headline image
    QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
    Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month. 
    Via Stocktwits
    News headline image
    Why Did CRMD Stock Tumble Over 11% Today? ↗
    The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗
    BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms. 
    Via Stocktwits
    News headline image
    Why Did CDXS Stock Jump 7% Today? ↗
    The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform. 
    Via Stocktwits
    IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗
    Via Stocktwits
    Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
    Via Stocktwits
    IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗
    Via Stocktwits
    News headline image
    AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗
    Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome. 
    Via Stocktwits
    News headline image
    AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗
    Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data. 
    Via Stocktwits
    News headline image
    VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗
    Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12. 
    Via Stocktwits
    News headline image
    ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗
    Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data 
    Via Stocktwits
    News headline image
    Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
    Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal. 
    Via Stocktwits
    News headline image
    SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗
    The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio. 
    Via Stocktwits
    News headline image
    CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
    COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
    Via Stocktwits
    News headline image
    CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
    The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
    Via Stocktwits
    News headline image
    HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗
    The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration. 
    Via Stocktwits
    News headline image
    Why Is ALVO Stock Rising Pre-Market Today? ↗
    The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints. 
    Via Stocktwits
    News headline image
    The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
    The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
    Via MarketMinute
    Topics ETFs Government Initial Public Offering
    News headline image
    Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
    Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. 
    Via Stocktwits
    News headline image
    Why Did SER Stock Surge Over 70% In Pre-Market Today? ↗
    The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease. 
    Via Stocktwits
    News headline image
    This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF ↗
    The iShares Biotechnology ETF tracks U.S. biotech firms, offering exposure to companies advancing research, development, and innovation. 
    Via The Motley Fool
    Topics Derivatives ETFs Regulatory Compliance
    News headline image
    2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
    Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
    Via The Motley Fool
    Topics ETFs Intellectual Property World Trade
    News headline image
    The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare
    The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence... 
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    News headline image
    Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
    The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
    Via Stocktwits
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    28 29 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.